Most solid tumors, including colorectal cancers, shed cell-free DNA (ctDNA) in the blood. ctDNA can be analyzed to generate molecular profiles which capture the heterogeneity of the disease more comprehensively then tumor tissue biopsies. This approach commonly called 'liquid biopsy' can be applied to monitor response to therapy, to assess minimal residual disease and to uncover the emergence of drug resistance. This review will discuss current and future developments of ctDNA analysis in the clinical management of colorectal cancer patients.
Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients
SIRAVEGNA, GIULIA;BARDELLI, Alberto
Last
2016-01-01
Abstract
Most solid tumors, including colorectal cancers, shed cell-free DNA (ctDNA) in the blood. ctDNA can be analyzed to generate molecular profiles which capture the heterogeneity of the disease more comprehensively then tumor tissue biopsies. This approach commonly called 'liquid biopsy' can be applied to monitor response to therapy, to assess minimal residual disease and to uncover the emergence of drug resistance. This review will discuss current and future developments of ctDNA analysis in the clinical management of colorectal cancer patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2016-Blood circulating_post print_4aperto.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
335.55 kB
Formato
Adobe PDF
|
335.55 kB | Adobe PDF | Visualizza/Apri |
|
2016-Blood circulating.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
265.52 kB
Formato
Adobe PDF
|
265.52 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
